Urinary perilipin 2 has been suggested as an early screening biomarker for RCC, which enables the differentiation between cancer patients and healthy controls, benign kidney tumours, noncancerous kidney diseases, and other cancers, including bladder and prostate cancers [211,212]. This evidence concerns the gene PLIN2 and renal cell carcinoma.